Following Protest, FDA Accepts Pharmacyclics’ Xcytrin NDA
This article was originally published in The Pink Sheet Daily
CEO tells “The Pink Sheet” DAILY data slated for release at upcoming medical conferences could further support approval.
You may also be interested in...
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.
Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.
CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.